Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma.

ABSTRACT:

Purpose

Minimal residual disease (MRD) negativity is a strong predictor for outcome in multiple myeloma. To assess V(D)J clonotype capture using the updated Adaptive next-generation sequencing (NGS) MRD assay in a clinical setting, we analyzed baseline and follow-up samples from patients with multiple myeloma who achieved deep clinical responses.

Experimental design

A total of 159 baseline and 31 follow-up samples from patients with multiple myeloma were sequenced using the NGS MRD assay. Baseline samples were also sequenced using a targeted multiple myeloma panel (myTYPE). We estimated ORs with 95% confidence intervals (CI) for clonotypes detection using logistic regression.

Results

The V(D)J clonotype capture rate was 93% in baseline samples with detectable genomic

SUBMITTER: Hultcrantz M 

PROVIDER: S-EPMC9179004 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature